Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial.

Carvalho Ade M., Badial PR., Álvarez LE., Yamada AL., Borges AS., Deffune E.

Randomized Controlled Trial on Tendon Injury, published in Stem Cell Res Ther (2013) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Stem Cell Res Ther (2013)
Country
England
Reported sample size
—
Source database
PubMed
PMID
23876512
PMCID
PMC3854756
DOI
10.1186/scrt236
Citations
70

Abstract (original English)

Introduction Tendon injury is a major cause of lameness and decreased performance in athletic equines. Various therapies for tendonitis have been described; however, none of these therapies results in complete tissue regeneration, and the injury recurrence rate is high even after long recovery periods involving rest and physiotherapy. Methods A lesion was induced with collagenase gel in the superficial digital flexor tendon in the center portion of the metacarpal region of eight equines of mixed breed. After two weeks, the lesions of the animals in the treated and control groups were treated through the intralesional administration of mesenchymal stem cells derived from adipose tissue (adMSCs) suspended in platelet concentrate (PC) and with phosphate buffered saline (PBS), respectively. Serial ultrasound analyses were performed every two weeks. After 16 weeks of therapy, a biopsy was performed for histopathological, immunohistochemical and gene expression (type I collagen (COL1A1), type III collagen (COL3A1), tenascin-C (TNC), tenomodulin (TNMD), and scleraxis (SCX)) analyses. Results Differences in the ultrasound and histopathological analyses were observed between the groups. Improved results were reported in the group treated with adMSCs suspended in PC. There was no difference in the gene expression levels observed after the different treatments. The main results observed f

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsBlood PlateletsCell- and Tissue-Based TherapyFemaleHorse DiseasesHorsesMaleMesenchymal Stem CellsTendon Injuries

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research